New combo therapy aims to personalize lung cancer treatment
NCT ID NCT07624487
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people with a specific type of advanced lung cancer (EGFR L858R mutation). It tests a treatment plan that starts with a targeted drug (aumolertinib) alone for 6 weeks, then adds chemotherapy for 4 cycles, and finally continues with the targeted drug alone. The goal is to see if early changes in tumor DNA in the blood can predict who benefits most, potentially allowing some patients to avoid chemotherapy in the future. About 50 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aumolertinib combined with pemetrexed and carboplatin chemotherapy
What this could lead to
If successful, this could lead to a more personalized treatment approach for EGFR L858R lung cancer, potentially sparing some patients from unnecessary chemotherapy while improving outcomes for others.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 50 participants, so results may not apply to everyone. Combining chemotherapy with a targeted drug also increases the risk of side effects like fatigue, nausea, and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shuang Ho Hospital
NOT_YET_RECRUITINGNew Taipei City, Taiwan
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taipei Medical University Hospital
RECRUITINGTaipei, Taiwan
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wanfang Hospital
NOT_YET_RECRUITINGTaipei, Taiwan
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••